XYOSTED Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xyosted, and when can generic versions of Xyosted launch?
Xyosted is a drug marketed by Antares Pharma Inc and is included in one NDA. There are twenty-three patents protecting this drug.
The generic ingredient in XYOSTED is testosterone enanthate. There are sixty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the testosterone enanthate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xyosted
A generic version of XYOSTED was approved as testosterone enanthate by NEXUS on June 14th, 2006.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for XYOSTED?
- What are the global sales for XYOSTED?
- What is Average Wholesale Price for XYOSTED?
Summary for XYOSTED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for XYOSTED |
| What excipients (inactive ingredients) are in XYOSTED? | XYOSTED excipients list |
| DailyMed Link: | XYOSTED at DailyMed |
US Patents and Regulatory Information for XYOSTED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-002 | Sep 28, 2018 | RX | Yes | Yes | 11,813,435 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-002 | Sep 28, 2018 | RX | Yes | Yes | 11,446,440 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | RX | Yes | Yes | 11,844,804 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | RX | Yes | Yes | 11,497,753 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-002 | Sep 28, 2018 | RX | Yes | Yes | 9,629,959 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
